Related Experiment Videos
Pulmonary thromboxane release following intestinal reperfusion
R H Turnage1, K M Kadesky, L Bartula
1Department of Surgery, University of Texas Southwestern Medical School at Dallas, USA.
The Journal of Surgical Research
|June 1, 1995
Summary
Intestinal reperfusion injury increases pulmonary thromboxane A2 (TxA2) release, leading to lung microvascular dysfunction. Inhibiting TxA2 production prevents this injury, highlighting its role in reperfusion-induced lung damage.
Area of Science:
- Physiology
- Pathology
- Biochemistry
Background:
- Intestinal reperfusion (IR) injury is known to cause lung injury.
- Microvascular dysfunction is a key feature of IR-induced lung injury.
Purpose of the Study:
- To investigate the hypothesis that IR induces pulmonary thromboxane A2 (TxA2) release.
- To determine if TxA2 contributes to pulmonary microvascular dysfunction following IR.
Main Methods:
- Sprague-Dawley rats underwent intestinal ischemia and reperfusion (IR) or sham operation.
- Lungs were perfused ex vivo, and eicosanoid levels (TxB2, 6-keto-PGF1a, PGE2) in pulmonary venous effluent and bronchoalveolar lavage (BAL) fluid were measured.
- Pulmonary artery pressure (PAP) was monitored; effects of cyclooxygenase and thromboxane synthetase inhibitors were assessed.
Main Results:
- The dominant eicosanoid generated in IR lungs was TxB2, with significantly elevated levels in pulmonary venous effluent and BAL fluid compared to controls.
- IR lungs exhibited a significant increase in pulmonary artery pressure (PAP).
- Administration of indomethacin (cyclooxygenase inhibitor) and imidazole (thromboxane synthetase inhibitor) prevented the IR-induced increase in PAP.
Conclusions:
- IR up-regulates endogenous pulmonary thromboxane A2 (TxA2) release.
- Local TxA2 release by the lung contributes to the microvascular dysfunction observed in IR-induced lung injury.
- Targeting TxA2 pathways may offer therapeutic strategies for IR-induced lung injury.